vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and BXP, Inc. (BXP). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $872.1M, roughly 1.1× BXP, Inc.). BXP, Inc. runs the higher net margin — 15.3% vs 0.7%, a 14.6% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 0.8%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 1.3%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.

ASTH vs BXP — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.1× larger
ASTH
$950.5M
$872.1M
BXP
Growing faster (revenue YoY)
ASTH
ASTH
+42.1% gap
ASTH
42.9%
0.8%
BXP
Higher net margin
BXP
BXP
14.6% more per $
BXP
15.3%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
1.3%
BXP

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASTH
ASTH
BXP
BXP
Revenue
$950.5M
$872.1M
Net Profit
$6.6M
$133.0M
Gross Margin
Operating Margin
1.9%
Net Margin
0.7%
15.3%
Revenue YoY
42.9%
0.8%
Net Profit YoY
184.4%
53.0%
EPS (diluted)
$0.12
$1.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
BXP
BXP
Q1 26
$872.1M
Q4 25
$950.5M
$877.1M
Q3 25
$956.0M
$871.5M
Q2 25
$654.8M
$868.5M
Q1 25
$620.4M
$865.2M
Q4 24
$665.2M
$858.6M
Q3 24
$478.7M
$859.2M
Q2 24
$486.3M
$850.5M
Net Profit
ASTH
ASTH
BXP
BXP
Q1 26
$133.0M
Q4 25
$6.6M
$248.4M
Q3 25
$373.0K
$-121.7M
Q2 25
$9.4M
$89.0M
Q1 25
$6.7M
$61.2M
Q4 24
$-7.8M
$-228.9M
Q3 24
$16.1M
$83.6M
Q2 24
$19.2M
$79.6M
Gross Margin
ASTH
ASTH
BXP
BXP
Q1 26
Q4 25
58.8%
Q3 25
59.3%
Q2 25
59.2%
Q1 25
59.2%
Q4 24
59.7%
Q3 24
59.5%
Q2 24
59.8%
Operating Margin
ASTH
ASTH
BXP
BXP
Q1 26
Q4 25
1.9%
Q3 25
2.0%
Q2 25
3.1%
Q1 25
3.3%
Q4 24
0.1%
Q3 24
5.9%
Q2 24
6.2%
Net Margin
ASTH
ASTH
BXP
BXP
Q1 26
15.3%
Q4 25
0.7%
28.3%
Q3 25
0.0%
-14.0%
Q2 25
1.4%
10.2%
Q1 25
1.1%
7.1%
Q4 24
-1.2%
-26.7%
Q3 24
3.4%
9.7%
Q2 24
3.9%
9.4%
EPS (diluted)
ASTH
ASTH
BXP
BXP
Q1 26
$1.69
Q4 25
$0.12
$1.56
Q3 25
$0.01
$-0.77
Q2 25
$0.19
$0.56
Q1 25
$0.14
$0.39
Q4 24
$-0.14
$-1.46
Q3 24
$0.33
$0.53
Q2 24
$0.40
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
BXP
BXP
Cash + ST InvestmentsLiquidity on hand
$429.5M
$512.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$7.7B
Total Assets
$2.2B
$25.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
BXP
BXP
Q1 26
$512.8M
Q4 25
$429.5M
$1.5B
Q3 25
$463.4M
$861.1M
Q2 25
$342.1M
$447.0M
Q1 25
$260.9M
$398.1M
Q4 24
$290.8M
$1.3B
Q3 24
$350.3M
$1.4B
Q2 24
$327.7M
$685.4M
Stockholders' Equity
ASTH
ASTH
BXP
BXP
Q1 26
$7.7B
Q4 25
$779.3M
$5.1B
Q3 25
$775.5M
$5.0B
Q2 25
$765.5M
$5.3B
Q1 25
$745.4M
$5.3B
Q4 24
$712.7M
$5.4B
Q3 24
$704.6M
$5.8B
Q2 24
$678.9M
$5.8B
Total Assets
ASTH
ASTH
BXP
BXP
Q1 26
$25.1B
Q4 25
$2.2B
$26.2B
Q3 25
$2.2B
$26.0B
Q2 25
$1.4B
$25.6B
Q1 25
$1.3B
$25.4B
Q4 24
$1.4B
$26.1B
Q3 24
$1.3B
$26.4B
Q2 24
$1.3B
$25.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
BXP
BXP
Operating Cash FlowLast quarter
$-2.9M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
1.5%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
BXP
BXP
Q1 26
Q4 25
$-2.9M
$407.8M
Q3 25
$10.0M
$274.2M
Q2 25
$90.9M
$353.1M
Q1 25
$16.6M
$210.0M
Q4 24
$-10.9M
$383.7M
Q3 24
$34.0M
$286.1M
Q2 24
$23.2M
$367.1M
Free Cash Flow
ASTH
ASTH
BXP
BXP
Q1 26
Q4 25
$-6.0M
$362.7M
Q3 25
$7.4M
$231.6M
Q2 25
$89.5M
$281.5M
Q1 25
$13.6M
$152.6M
Q4 24
$-13.5M
$312.5M
Q3 24
$31.7M
$234.5M
Q2 24
$20.4M
$332.4M
FCF Margin
ASTH
ASTH
BXP
BXP
Q1 26
Q4 25
-0.6%
41.4%
Q3 25
0.8%
26.6%
Q2 25
13.7%
32.4%
Q1 25
2.2%
17.6%
Q4 24
-2.0%
36.4%
Q3 24
6.6%
27.3%
Q2 24
4.2%
39.1%
Capex Intensity
ASTH
ASTH
BXP
BXP
Q1 26
1.5%
Q4 25
0.3%
5.1%
Q3 25
0.3%
4.9%
Q2 25
0.2%
8.2%
Q1 25
0.5%
6.6%
Q4 24
0.4%
8.3%
Q3 24
0.5%
6.0%
Q2 24
0.6%
4.1%
Cash Conversion
ASTH
ASTH
BXP
BXP
Q1 26
Q4 25
-0.44×
1.64×
Q3 25
26.69×
Q2 25
9.65×
3.97×
Q1 25
2.48×
3.43×
Q4 24
Q3 24
2.11×
3.42×
Q2 24
1.21×
4.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

BXP
BXP

Lease$818.2M94%
Parking and other$30.8M4%
Development and management services$9.2M1%

Related Comparisons